Cargando…

The effect and therapeutic compliance of adjuvant therapy in patients with cholangiocarcinoma after R0 resection: a retrospective study

BACKGROUND: This study aimed to compare clinical outcomes between surveillance and adjuvant therapy (AT) groups after R0 resection for cholangiocarcinoma (CCA). METHODS: A total of 154 patients who underwent R0 resection for CCA at the Daegu Catholic University Medical Center between January 2010 an...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeong, Han Taek, Lee, Joonkee, Jo, Hyeong Ho, Kim, Ho Gak, Han, Jimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of Yeungnam Medical Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946916/
https://www.ncbi.nlm.nih.gov/pubmed/35615785
http://dx.doi.org/10.12701/jyms.2022.00213
_version_ 1784892438646620160
author Jeong, Han Taek
Lee, Joonkee
Jo, Hyeong Ho
Kim, Ho Gak
Han, Jimin
author_facet Jeong, Han Taek
Lee, Joonkee
Jo, Hyeong Ho
Kim, Ho Gak
Han, Jimin
author_sort Jeong, Han Taek
collection PubMed
description BACKGROUND: This study aimed to compare clinical outcomes between surveillance and adjuvant therapy (AT) groups after R0 resection for cholangiocarcinoma (CCA). METHODS: A total of 154 patients who underwent R0 resection for CCA at the Daegu Catholic University Medical Center between January 2010 and December 2019 were included. Overall survival (OS) and progression-free survival (PFS) were analyzed. RESULTS: The median follow-up duration was 899 days. There were 109 patients in the AT group and 45 patients in the surveillance group. The patients in the AT group were younger (67 years vs. 74 years, p<0.001) and included more males (64.2% vs. 46.7%, p=0.044). The proportion of patients with stage III CCA was larger in the AT group than in the surveillance group (13.8% vs. 2.2%, p=0.005). In addition, AT did not improve OS (5-year OS rate, 69.3% in the AT group vs. 64.2% in the surveillance group, p=0.806) or PFS (5-year PFS rate, 42.6% in the AT group vs. 48.9% in the surveillance group, p=0.113). In multivariate analysis using the Cox proportional hazards model, stage III CCA (hazard ratio [HR], 10.81; 95% confidence interval [CI], 2.92–40.00; p<0.001) was a significant predictor of OS. American Society of Anesthesiologists classification II (HR, 0.50; 95% CI, 0.31–0.81; p=0.005), and American Joint Committee on Cancer stages II (HR, 3.14; 95% CI, 1.25–7.89; p=0.015) and III (HR, 8.08; 95% CI, 2.80–23.32; p<0.001) were independent predictors of PFS. CONCLUSION: AT after R0 resection for CCA did not improve OS or PFS.
format Online
Article
Text
id pubmed-9946916
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Journal of Yeungnam Medical Science
record_format MEDLINE/PubMed
spelling pubmed-99469162023-02-24 The effect and therapeutic compliance of adjuvant therapy in patients with cholangiocarcinoma after R0 resection: a retrospective study Jeong, Han Taek Lee, Joonkee Jo, Hyeong Ho Kim, Ho Gak Han, Jimin J Yeungnam Med Sci Original Article BACKGROUND: This study aimed to compare clinical outcomes between surveillance and adjuvant therapy (AT) groups after R0 resection for cholangiocarcinoma (CCA). METHODS: A total of 154 patients who underwent R0 resection for CCA at the Daegu Catholic University Medical Center between January 2010 and December 2019 were included. Overall survival (OS) and progression-free survival (PFS) were analyzed. RESULTS: The median follow-up duration was 899 days. There were 109 patients in the AT group and 45 patients in the surveillance group. The patients in the AT group were younger (67 years vs. 74 years, p<0.001) and included more males (64.2% vs. 46.7%, p=0.044). The proportion of patients with stage III CCA was larger in the AT group than in the surveillance group (13.8% vs. 2.2%, p=0.005). In addition, AT did not improve OS (5-year OS rate, 69.3% in the AT group vs. 64.2% in the surveillance group, p=0.806) or PFS (5-year PFS rate, 42.6% in the AT group vs. 48.9% in the surveillance group, p=0.113). In multivariate analysis using the Cox proportional hazards model, stage III CCA (hazard ratio [HR], 10.81; 95% confidence interval [CI], 2.92–40.00; p<0.001) was a significant predictor of OS. American Society of Anesthesiologists classification II (HR, 0.50; 95% CI, 0.31–0.81; p=0.005), and American Joint Committee on Cancer stages II (HR, 3.14; 95% CI, 1.25–7.89; p=0.015) and III (HR, 8.08; 95% CI, 2.80–23.32; p<0.001) were independent predictors of PFS. CONCLUSION: AT after R0 resection for CCA did not improve OS or PFS. Journal of Yeungnam Medical Science 2022-05-26 /pmc/articles/PMC9946916/ /pubmed/35615785 http://dx.doi.org/10.12701/jyms.2022.00213 Text en Copyright © 2023 Yeungnam University College of Medicine, Yeungnam University Institute of Medical Science https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Jeong, Han Taek
Lee, Joonkee
Jo, Hyeong Ho
Kim, Ho Gak
Han, Jimin
The effect and therapeutic compliance of adjuvant therapy in patients with cholangiocarcinoma after R0 resection: a retrospective study
title The effect and therapeutic compliance of adjuvant therapy in patients with cholangiocarcinoma after R0 resection: a retrospective study
title_full The effect and therapeutic compliance of adjuvant therapy in patients with cholangiocarcinoma after R0 resection: a retrospective study
title_fullStr The effect and therapeutic compliance of adjuvant therapy in patients with cholangiocarcinoma after R0 resection: a retrospective study
title_full_unstemmed The effect and therapeutic compliance of adjuvant therapy in patients with cholangiocarcinoma after R0 resection: a retrospective study
title_short The effect and therapeutic compliance of adjuvant therapy in patients with cholangiocarcinoma after R0 resection: a retrospective study
title_sort effect and therapeutic compliance of adjuvant therapy in patients with cholangiocarcinoma after r0 resection: a retrospective study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946916/
https://www.ncbi.nlm.nih.gov/pubmed/35615785
http://dx.doi.org/10.12701/jyms.2022.00213
work_keys_str_mv AT jeonghantaek theeffectandtherapeuticcomplianceofadjuvanttherapyinpatientswithcholangiocarcinomaafterr0resectionaretrospectivestudy
AT leejoonkee theeffectandtherapeuticcomplianceofadjuvanttherapyinpatientswithcholangiocarcinomaafterr0resectionaretrospectivestudy
AT johyeongho theeffectandtherapeuticcomplianceofadjuvanttherapyinpatientswithcholangiocarcinomaafterr0resectionaretrospectivestudy
AT kimhogak theeffectandtherapeuticcomplianceofadjuvanttherapyinpatientswithcholangiocarcinomaafterr0resectionaretrospectivestudy
AT hanjimin theeffectandtherapeuticcomplianceofadjuvanttherapyinpatientswithcholangiocarcinomaafterr0resectionaretrospectivestudy
AT jeonghantaek effectandtherapeuticcomplianceofadjuvanttherapyinpatientswithcholangiocarcinomaafterr0resectionaretrospectivestudy
AT leejoonkee effectandtherapeuticcomplianceofadjuvanttherapyinpatientswithcholangiocarcinomaafterr0resectionaretrospectivestudy
AT johyeongho effectandtherapeuticcomplianceofadjuvanttherapyinpatientswithcholangiocarcinomaafterr0resectionaretrospectivestudy
AT kimhogak effectandtherapeuticcomplianceofadjuvanttherapyinpatientswithcholangiocarcinomaafterr0resectionaretrospectivestudy
AT hanjimin effectandtherapeuticcomplianceofadjuvanttherapyinpatientswithcholangiocarcinomaafterr0resectionaretrospectivestudy